Centiva Capital LP Invests $265,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Centiva Capital LP bought a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 18,630 shares of the company’s stock, valued at approximately $265,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Catalytic Wealth RIA LLC lifted its stake in Takeda Pharmaceutical by 4.0% in the 2nd quarter. Catalytic Wealth RIA LLC now owns 21,703 shares of the company’s stock valued at $281,000 after purchasing an additional 841 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 38.6% in the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock valued at $43,000 after buying an additional 859 shares during the last quarter. Hexagon Capital Partners LLC boosted its stake in shares of Takeda Pharmaceutical by 34.3% during the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after acquiring an additional 1,129 shares during the period. Gallacher Capital Management LLC increased its holdings in shares of Takeda Pharmaceutical by 7.0% during the 2nd quarter. Gallacher Capital Management LLC now owns 17,365 shares of the company’s stock worth $225,000 after acquiring an additional 1,136 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. raised its stake in Takeda Pharmaceutical by 3.3% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 41,974 shares of the company’s stock valued at $543,000 after acquiring an additional 1,347 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

NYSE:TAK opened at $13.57 on Thursday. The company has a market cap of $43.16 billion, a P/E ratio of 23.39, a P/E/G ratio of 0.25 and a beta of 0.51. The firm’s fifty day moving average price is $13.86 and its two-hundred day moving average price is $13.88. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.